Rising thyroglobulin with a negative neck ultrasound after thyroid cancer treatment
A 47-year-old woman had a total thyroidectomy 3 years ago for a 3.5 cm papillary thyroid carcinoma with central and lateral neck nodal metastases (pT2 pN1b). She received remnant ablation with 3.7 GBq (100 mCi) of iodine-131 after recombinant TSH, and the post-therapy scan showed uptake only in the thyroid bed. She is now on levothyroxine with a suppressed TSH of 0.05 mIU/L. Her latest stimulated thyroglobulin is 18 ng/mL with negative anti-thyroglobulin antibodies. Ultrasound of the neck shows no residual thyroid tissue and no suspicious lymph nodes; the largest node is 6 mm with a normal hilum. She feels well and has no other comorbidity; renal function is normal. The nuclear medicine physician is asked to decide between a further radioiodine scan, empirical radioiodine treatment, and FDG PET/CT.
1. Interpret the thyroglobulin result and choose the next investigation, with reasoning.
Read the worked answer
A stimulated thyroglobulin of 18 ng/mL with negative anti-thyroglobulin antibodies, after total thyroidectomy and successful remnant ablation, indicates persistent or recurrent disease until proven otherwise. A value above about 10 ng/mL on stimulation is the threshold at which further imaging is generally pursued; below 1 ng/mL with negative antibodies would be an excellent response.
Before proceeding, confirm the result is real:
- Same assay and same laboratory as previous values; ideally the same method over time.
- Anti-thyroglobulin antibodies genuinely negative (they cause falsely low values).
- Exclude assay interference (heterophile antibodies) if the value is implausibly high or discordant.
Next investigation: a recombinant TSH-stimulated diagnostic iodine-131 whole-body scan with SPECT/CT.
Reasoning: it is the only test that maps functional iodine-avid disease, it guides whether further radioiodine will be therapeutic, and SPECT/CT localises uptake that planar imaging alone misassigns - particularly thyroid bed versus nodal versus physiological activity. The diagnostic activity (about 74–185 MBq) is small, so stunning is a minimal concern with modern practice.
Why not empirical radioiodine straight away: treating blind risks an unnecessary large dose, and could miss a surgically resectable nodal recurrence or a non-iodine-avid dedifferentiated focus that would be better imaged with FDG PET/CT.
2. The recombinant TSH-stimulated iodine-131 scan shows focal uptake in the thyroid bed only, with no distant uptake, and thyroglobulin remains 16 ng/mL. How do you manage this?
Read the worked answer
Interpretation: the uptake is in the thyroid bed, which usually means residual benign or malignant tissue at the surgical bed rather than distant metastasis. A thyroglobulin of 16 ng/mL with a small thyroid-bed focus suggests a modest remnant or a small local recurrence - a biochemically incomplete response at most.
Options, in order of preference:
- Assess the bed with dedicated ultrasound and, if there is a discrete nodule, FNA with thyroglobulin washout. Surgical resection of a focal recurrence is preferred over further radioiodine when the disease is operable - it gives histology and avoids repeated large activities.
- Additional radioiodine (for example 3.7–5.5 GBq) if the bed uptake is substantial, if surgery is not feasible or would risk the recurrent laryngeal nerve, or if there is no discrete surgical target. Reassess with a post-therapy scan and thyroglobulin 6–12 months later.
- Active surveillance with serial thyroglobulin and ultrasound is reasonable if the uptake is small, stable and the patient is low risk; not every patient with a detectable thyroglobulin needs treatment.
In all cases, keep TSH suppressed but not fully ablated, avoid overtreatment, and document the response category (excellent, indeterminate, biochemically incomplete, structurally incomplete) at each review, because it drives the next decision.
3. What is the role of FDG PET/CT if the iodine scan is negative?
Read the worked answer
This is the classic setting for FDG PET/CT in thyroid cancer: a raised thyroglobulin with a negative iodine-131 scan (sometimes called the TENIS syndrome).
- Sensitivity is highest when the thyroglobulin is above about 10 ng/mL on stimulation, reaching roughly 70–80%; below that it falls sharply and the test is less useful.
- Value: it detects nodal and distant disease that is not iodine-avid - that is, dedifferentiated tumour, which will not respond to further radioiodine. It changes management in a substantial minority of patients, typically by directing surgery, external-beam radiotherapy or systemic therapy.
- Prognosis: FDG avidity in differentiated thyroid cancer is an adverse prognostic marker, particularly when the tumour is iodine-refractory; a negative PET in a patient with a modest thyroglobulin is reassuring.
- Also indicated in high-risk histology (tall cell, hobnail variants), in poorly differentiated or anaplastic tumours for staging, and when thyroglobulin is rising rapidly even if the level is low.
Practical sequence: negative diagnostic iodine scan → proceed to FDG PET/CT rather than empirical radioiodine. If PET is also negative and thyroglobulin is modest and stable, surveillance is often appropriate; if it is rising rapidly, consider further anatomical imaging and repeat sampling. Check that TSH is adequately elevated or use recombinant TSH before PET, since TSH stimulation increases FDG uptake in thyroid tissue.